FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200433574> ?p ?o ?g. }

• W4200433574 abstract "Treatment of COVID-19-associated pneumonia in the overwhelming majority of cases is accompanied by empirical prescription of antibiotic therapy. According to a number of studies carried out, the addition of a bacterial infection in this disease is noted less often than in other viral pneumonias, in particular, caused by the influenza virus. In addition, the occurrence of leukocytosis in response to therapy with glucocorticosteroids (GCS) is often perceived as an attachment of bacterial flora and is the reason for initiating antibiotic therapy. Therefore, an urgent task is the correct interpretation of leukocytosis in response to GCS therapy in COVID-19. The purpose of the work was to study the dynamics of changes in the number of leukocytes, neutrophils and monocytes of venous blood in patients with moderate COVID-19 with systemic use of GCS. Also we aimed to determine the differences in these indicators between the group of patients with indirect signs of bacterial infection and the group of patients receiving GCS. We analyzed the indicators of the complete blood count of 154 patients in the temporary infectious diseases hospital in the “PATRIOT” Park of the Moscow region with confirmed moderate form of COVID-19. The comparison group (1) consisted of 128 patients without clinical signs of bacterial infection and leukocytosis on admission, who were prescribed GCS therapy. The control group (2) consisted of 26 people who, upon admission, showed signs of a bacterial infection - a cough with purulent sputum in combination with neutrophilic leukocytosis. The dynamics of cells in venous blood was assessed in patients of group (1) before the start, 3 and 6 days after the start of GCS therapy. We also compared the number of leukocytes, neutrophils and monocytes between patients with developed leukocytosis from group (1) in response to GCS therapy and group (2). As a result of the study, an increase in the number of leukocytes, neutrophils and monocytes was revealed according to the data of the complete blood count test in patients of the group (1) on days 3 and 6 of GCS therapy. All patients with developed leukocytosis (103 people) had no clinical signs of bacterial infection. In patients with developed leukocytosis from group (1), an increase in the number of monocytes was revealed (0.90 (0.84; 1.02) on day 3 of GCS and 0.94 (0.87; 1.26) on day 6 of GCS) compared with group (2) (0.61 (0.50; 0.71)), p <0.001. The number of leukocytes and neutrophils did not differ between the groups. The appearance of monocytosis when taking GCS may be due to the presence of macrophage activation syndrome in the pathogenesis of COVID-19 and, therefore, increased activation of monocytes. The use of GCS in this case leads to inhibition of the migration of monocytes to the inflammation area and to the stimulation of the production of their anti-inflammatory pool (M2 cells) by the bone marrow. This fact causes an increase in the number of monocytes in the peripheral blood. Monocytosis in response to GCS therapy can be a differential diagnostic criterion between glucocorticoid-induced leukocytosis and the addition of a bacterial infection. This may be one of the factors influencing the decision to prescribe antibiotic therapy, and may also be a criterion for the effectiveness of GCS immunosuppressive therapy in COVID-19, which requires further study." @default.
• W4200433574 created "2021-12-31" @default.
• W4200433574 creator A5006553248 @default.
• W4200433574 creator A5011213517 @default.
• W4200433574 creator A5012563885 @default.
• W4200433574 creator A5060601133 @default.
• W4200433574 creator A5069429663 @default.
• W4200433574 creator A5069755885 @default.
• W4200433574 creator A5071328537 @default.
• W4200433574 creator A5076024635 @default.
• W4200433574 creator A5082518851 @default.
• W4200433574 creator A5083364334 @default.
• W4200433574 date "2021-12-03" @default.
• W4200433574 modified "2023-10-15" @default.
• W4200433574 title "Differential and diagnostic significance of monocytosis in treatment of moderate forms of COVID-19" @default.
• W4200433574 doi "https://doi.org/10.15789/2220-7619-ada-1681" @default.
• W4200433574 hasPublicationYear "2021" @default.
• W4200433574 type Work @default.
• W4200433574 citedByCount "0" @default.
• W4200433574 crossrefType "journal-article" @default.
• W4200433574 hasAuthorship W4200433574A5006553248 @default.
• W4200433574 hasAuthorship W4200433574A5011213517 @default.
• W4200433574 hasAuthorship W4200433574A5012563885 @default.
• W4200433574 hasAuthorship W4200433574A5060601133 @default.
• W4200433574 hasAuthorship W4200433574A5069429663 @default.
• W4200433574 hasAuthorship W4200433574A5069755885 @default.
• W4200433574 hasAuthorship W4200433574A5071328537 @default.
• W4200433574 hasAuthorship W4200433574A5076024635 @default.
• W4200433574 hasAuthorship W4200433574A5082518851 @default.
• W4200433574 hasAuthorship W4200433574A5083364334 @default.
• W4200433574 hasBestOaLocation W42004335741 @default.
• W4200433574 hasConcept C126322002 @default.
• W4200433574 hasConcept C142724271 @default.
• W4200433574 hasConcept C177713679 @default.
• W4200433574 hasConcept C203014093 @default.
• W4200433574 hasConcept C2776301714 @default.
• W4200433574 hasConcept C2776345407 @default.
• W4200433574 hasConcept C2777914695 @default.
• W4200433574 hasConcept C2778923028 @default.
• W4200433574 hasConcept C2780007613 @default.
• W4200433574 hasConcept C2781069245 @default.
• W4200433574 hasConcept C2781087989 @default.
• W4200433574 hasConcept C2781347865 @default.
• W4200433574 hasConcept C71924100 @default.
• W4200433574 hasConceptScore W4200433574C126322002 @default.
• W4200433574 hasConceptScore W4200433574C142724271 @default.
• W4200433574 hasConceptScore W4200433574C177713679 @default.
• W4200433574 hasConceptScore W4200433574C203014093 @default.
• W4200433574 hasConceptScore W4200433574C2776301714 @default.
• W4200433574 hasConceptScore W4200433574C2776345407 @default.
• W4200433574 hasConceptScore W4200433574C2777914695 @default.
• W4200433574 hasConceptScore W4200433574C2778923028 @default.
• W4200433574 hasConceptScore W4200433574C2780007613 @default.
• W4200433574 hasConceptScore W4200433574C2781069245 @default.
• W4200433574 hasConceptScore W4200433574C2781087989 @default.
• W4200433574 hasConceptScore W4200433574C2781347865 @default.
• W4200433574 hasConceptScore W4200433574C71924100 @default.
• W4200433574 hasLocation W42004335741 @default.
• W4200433574 hasLocation W42004335742 @default.
• W4200433574 hasOpenAccess W4200433574 @default.
• W4200433574 hasPrimaryLocation W42004335741 @default.
• W4200433574 hasRelatedWork W1592484585 @default.
• W4200433574 hasRelatedWork W1859432097 @default.
• W4200433574 hasRelatedWork W1883141713 @default.
• W4200433574 hasRelatedWork W2000307078 @default.
• W4200433574 hasRelatedWork W2052909147 @default.
• W4200433574 hasRelatedWork W2196143462 @default.
• W4200433574 hasRelatedWork W2408777813 @default.
• W4200433574 hasRelatedWork W4200433574 @default.
• W4200433574 hasRelatedWork W4232132300 @default.
• W4200433574 hasRelatedWork W2338436140 @default.
• W4200433574 isParatext "false" @default.
• W4200433574 isRetracted "false" @default.
• W4200433574 workType "article" @default.